Clinical trials
SARS CoV 2 Infection clinical trials
Below are recruiting sars cov 2 infection clinical trials, each written for real people, not researchers. We’re tracking 70 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04424992Recruiting
Observing hospitalized adults with COVID-19 lung infection
This study follows adults who are hospitalized with COVID-19 in the lungs. The goal is to better understand how COVID-19 behaves in the hospital over time.
MonzaAges 18 years+ - NCT04896606RecruitingPhase 1/Phase 2
Matched donor immune therapy for mild to moderate COVID-19
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
Valhalla, New YorkAges 18–65 - NCT07224490RecruitingPhase 1
Kisspeptin test for brain function after COVID-19
This study tests how the brain's reproductive hormone system works after a COVID-19 infection using a substance called kisspeptin. It may help explain symptoms like changes in periods or hormone levels in people with long COVID.
Boston, MassachusettsAges 18–60 - NCT07536308RecruitingPhase 1
Nasal COVID-19 booster vaccine safety trial
This trial tests a new nasal spray COVID-19 booster vaccine. It aims to see if the vaccine is safe and produces a strong immune response when given through the nose and inhaled, in people who have already been vaccinated.
Decatur, GeorgiaAges 18–64 - NCT05218356RecruitingPhase 2
Codivir trial for hospitalized moderate COVID-19
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
Paulo Prata, Barretos/SP/BRAAges 18–75 - NCT05458440Recruiting
Study using immune cells from recovered COVID-19 donors
This study collects immune cells from people who recovered from COVID-19 and may use them to boost protection against SARS-CoV-2. It’s for hospitalized patients who already show a certain level of COVID-19 fighting immune response.
Vandœuvre-lès-Nancy, LorraineAges 18–70 - NCT05886816RecruitingPhase 2
Mitoquinone pills to prevent COVID-19 after risky exposure
This trial tests whether an oral medication (mitoquinone/mitoquinol) taken after a high-risk COVID-19 exposure can help prevent you from becoming sick. It is designed for people who currently have no symptoms but had a significant exposure to someone with confirmed COVID-19.
Dallas, TexasAges 18–65 - NCT06585241RecruitingPhase 4
Study of Updated COVID-19 Vaccines for High-Risk Groups
This trial tests updated COVID-19 vaccines designed to better protect against current variants. It's for people who have already been vaccinated and are at higher risk for severe COVID-19.
Atlanta, GeorgiaAges 6 months+ - NCT06635525Recruiting
How kidney failure affects your flu shot response
This study looks at how well the flu vaccine works in people with kidney failure who are on dialysis compared to healthy people. It will help doctors understand how kidney problems affect the body’s immune response to vaccination.
MilanAges 18–70 - NCT06784739Recruiting
COVID-19 immunity study for hospital staff and patients
This study looks at how the immune system responds to COVID-19 in healthcare workers and infected patients at Danderyd Hospital. It aims to understand immunity and help guide future care.
StockholmAges 18 years+ - NCT07021794RecruitingPhase 2
Antibody treatment for Long COVID symptoms
This study tests whether a lab-made antibody (sipavibart) can reduce Long COVID symptoms. It is for people who developed Long COVID after a confirmed COVID infection and still have moderate to severe fatigue and other ME/CFS-like symptoms.
Fort Lauderdale, FloridaAges 18–70 - NCT07278388Recruiting
Fatigue and brain fog in long COVID: a brain study
This trial uses brain scans to understand why people with long COVID feel very tired or have trouble thinking clearly. It could help find new treatments for these symptoms.
Baltimore, MarylandAges 18–75 - NCT07256795Enrolling by invitation
ME/CFS after COVID-19 vs. before the pandemic
This study looks at how the brain's protective barrier and immune system work in people with ME/CFS, comparing those who got sick before the COVID-19 pandemic to those who developed ME/CFS after a COVID-19 infection. It aims to understand why some people have lasting brain fog, fatigue, and other neuropsychiatric symptoms.
Baltimore, MarylandAges 18–70 - NCT05787418Enrolling by invitationPhase 3
Nasal spray to prevent COVID-19 after a close exposure
This Phase 3 trial tests whether a medicated nasal spray can stop COVID-19 from starting after you’ve been exposed to someone who recently tested positive. You must start very soon after the person became symptomatic, and you’ll be checked for eligibility based on timing and your health history.
BeijingAges 12–85 - NCT05350774Enrolling by invitationPhase 2
IV immunotherapy for lingering neurologic effects after COVID-19
This Phase 2 trial tests whether intravenous immunotherapy (IVIG) can improve ongoing neurologic symptoms after a mild-to-moderate COVID-19 illness. It targets people with persistent symptoms such as brain fog, fatigue, trouble thinking, dizziness when standing, and balance or other neurologic problems.
Bethesda, MarylandAges 18–100 - NCT05131594Enrolling by invitation
Study immune response in Long COVID patients
This trial studies how your immune system responds in people with Long COVID after a past COVID-19 infection. It may help researchers understand why symptoms linger and how the body’s response could be targeted.
Pasadena, CaliforniaAges 18 years+ - NCT06775457Recruiting
Genetic study of HERVs in children with new inflammation
This study looks at certain genes (called HERVs) in children with new inflammatory conditions like Kawasaki disease, COVID-19, or other infections. It aims to learn more about how these genes might be involved in the body's response to illness.
Carpi, ModenaAges Up to 18 years - NCT07243249Recruiting
Quick virus test to guide antibiotic use
This study tests whether a quick test for COVID-19, flu, and RSV can help doctors avoid giving antibiotics when they aren't needed. It's for people with fever or chest infection symptoms who are not sick enough to be hospitalized.
GarchesAges 1 year+ - NCT06914635Recruiting
Immunotherapy hub study for liver tumor patients
This trial is checking how the immune system works in people with primary liver cancer, looking at ways to prevent infections and manage the tumor. It is an observational study—meaning no new treatments are given—so it helps doctors learn more without adding extra medications.
Pavia, PaviaAges 18–90 - NCT06999603RecruitingPhase 2
Inhaled study drug for virus infections on ventilators
This study tests an inhaled study drug (SNG001) for adults on a breathing machine in the ICU due to a viral lung infection. The goal is to see if the drug can help patients recover faster.
Sacramento, CaliforniaAges 18 years+ - NCT07215273RecruitingPhase 2
Testing a new antifungal for mold infections in immunocompromised people
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
Birmingham, AlabamaAges 18 years+ - NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years
Hear when a new SARS CoV 2 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sars cov 2 infection?
- Yes. Clin2 currently lists 70 recruiting sars cov 2 infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sars cov 2 infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sars cov 2 infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.